Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Estrogen signaling influences cancer development and treatment efficacy.
• MDM4, a regulator of p53, exhibits dual roles in cancer: promoting transformation and sensitizing cells to DNA damage.
• Emerging data suggest a link between estrogen activity, gender, and MDM4 function in cancer.

Purpose of the Study:

• To investigate the in vivo impact of estrogens on the dual activities of MDM4.
• To explore the role of gender in MDM4-mediated chemo- and radio-sensitivity.
• To assess the therapeutic potential of combining anti-estrogenic agents with chemotherapy in MDM4-expressing tumors.

Main Methods:

• Utilized Mdm4 transgenic mouse models to study tumor formation and treatment sensitivity.
• Administered cisplatin and fulvestrant (a selective estrogen receptor degrader) in combination therapy.
• Analyzed molecular mechanisms including intracellular localization of MDM4 and p53-independent pathways.
• Correlated MDM4 nuclear localization and estrogen levels with clinical outcomes in ovarian cancer patients.

Main Results:

• Mdm4 transgenic mice showed accelerated fibrosarcoma formation and increased cisplatin sensitivity.
• MDM4 enhanced chemo- and radio-sensitivity in male mice but not in female mice.
• Combination therapy with fulvestrant restored cisplatin sensitivity in female mice.
• Estrogen receptor-α mediated increased nuclear localization of MDM4, decreasing cell death independently of p53.
• Increased MDM4 nuclear localization and intratumoral estrogen correlated with reduced platinum sensitivity, apoptosis, and poor disease-free survival in ovarian cancer.

Conclusions:

• Estrogens modulate the chemo-sensitivity of MDM4-expressing tumors, contributing to sexual dimorphism in treatment response.
• Estrogen receptor signaling impacts MDM4 intracellular trafficking, affecting cell death pathways.
• Targeting estrogen signaling in combination with chemotherapy represents a promising therapeutic strategy for MDM4-expressing cancers, particularly in female patients.